product name Tolazoline HCl
Description: Tolazoline is a non-selective competitive α-adrenergic receptor antagonist. Tolazoline is a pulmonary vasodilator indicated used to decrease pulmonary vascular resistance (PVR) in persistent pulmonary hypertension of the newborn (PPHN). Tolazoline has moderate alpha-adrenergic blocking activity and has histamine agonist activity. Tolazoline usually reduces pulmonary arterial pressure and vascular resistance.
References: J Cardiovasc Pharmacol. 1998 May;31(5):721-33; Ann Thorac Surg. 2006 Jan;81(1):125-31.
196.68
Formula
C10H12N2.HCl
CAS No.
59-97-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 39 mg/mL (198.3 mM)
Water: 39 mg/mL (198.3 mM)
Ethanol:
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19398921
| In Vitro |
In vitro activity: Tolazoline is a pulmonary vasodilator indicated used to decrease pulmonary vascular resistance (PVR) in persistent pulmonary hypertension of the newborn (PPHN). Tolazoline has moderate alpha-adrenergic blocking activity and has histamine agonist activity. Tolazoline usually reduces pulmonary arterial pressure and vascular resistance. Tolazoline is not as broadly effective as SNP against all spasmogens investigated. However, it may be effective in counteracting alpha-adrenoceptor-mediated vasospasm in human radial arteries. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | J Cardiovasc Pharmacol. 1998 May;31(5):721-33; Ann Thorac Surg. 2006 Jan;81(1):125-31. |
Related Posts
product name Tolazoline HCl
Description: Tolazoline is a non-selective competitive α-adrenergic receptor antagonist. Tolazoline is a pulmonary vasodilator indicated used to decrease pulmonary vascular resistance (PVR) in persistent pulmonary hypertension of the newborn (PPHN). Tolazoline has moderate alpha-adrenergic blocking activity and has histamine agonist activity. Tolazoline usually reduces pulmonary arterial pressure and vascular resistance.
References: J Cardiovasc Pharmacol. 1998 May;31(5):721-33; Ann Thorac Surg. 2006 Jan;81(1):125-31.
196.68
Formula
C10H12N2.HCl
CAS No.
59-97-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 39 mg/mL (198.3 mM)
Water: 39 mg/mL (198.3 mM)
Ethanol:
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19398921
| In Vitro |
In vitro activity: Tolazoline is a pulmonary vasodilator indicated used to decrease pulmonary vascular resistance (PVR) in persistent pulmonary hypertension of the newborn (PPHN). Tolazoline has moderate alpha-adrenergic blocking activity and has histamine agonist activity. Tolazoline usually reduces pulmonary arterial pressure and vascular resistance. Tolazoline is not as broadly effective as SNP against all spasmogens investigated. However, it may be effective in counteracting alpha-adrenoceptor-mediated vasospasm in human radial arteries. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | J Cardiovasc Pharmacol. 1998 May;31(5):721-33; Ann Thorac Surg. 2006 Jan;81(1):125-31. |